MARKET

OCX

OCX

ONCOCYTE
AMEX

Real-time Quotes | Nasdaq Last Sale

1.950
-0.010
-0.51%
After Hours: 1.930 -0.02 -1.03% 17:21 12/03 EST
OPEN
1.960
PREV CLOSE
1.960
HIGH
2.010
LOW
1.926
VOLUME
301.00K
TURNOVER
--
52 WEEK HIGH
3.510
52 WEEK LOW
1.150
MARKET CAP
131.14M
P/E (TTM)
-3.8168
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Where Do Hedge Funds Stand On OncoCyte Corporation (OCX)?
After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
Insider Monkey · 3d ago
Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference
Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Piper Sandler Virtual Healthcare Conference on Tuesday, December 1, 2020.
GlobeNewswire · 11/18 21:05
Oncocyte to Participate at 32nd Annual Piper Sandler Virtual Healthcare Conference
IRVINE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming Piper Sandler Virtual Healthcare Conference on Tuesday, December 1, 2020. About Oncocyte Corporation Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. TheraSure is a trademark of Chronix Biomedical, Inc.Investor Contact Bob Yedid LifeSci Advisors, LLC 646-597-6989 bob@lifesciadvisors.comMedia Contact Cait Williamson, Ph.D. LifeSci Communications, LLC 646-751-4366 cait@lifescicomms.comSource: Oncocyte Corporation
GlobeNewswire · 11/18 21:05
Oncocyte Highlights Presentation Of New Data On Its DetermaIO Test At Association For Molecular Pathology Conference
Oncocyte Corporation (NYSE:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the presentation of data on its
Benzinga · 11/18 13:07
Oncocyte Presents New Data on Its DetermaIO Test at Association for Molecular Pathology (AMP) 2020 Conference
GlobeNewswire · 11/18 13:00
Need To Know: Analysts Are Much More Bullish On OncoCyte Corporation (NYSEMKT:OCX) Revenues
Simply Wall St. · 11/18 04:55
Analysts Are Upgrading OncoCyte Corporation (NYSEMKT:OCX) After Its Latest Results
Shareholders of OncoCyte Corporation (NYSEMKT:OCX) will be pleased this week, given that the stock price is up 10% to...
Simply Wall St. · 11/16 10:49
OncoCyte EPS in-line, beats on revenue
OncoCyte (OCX): Q3 GAAP EPS of -$0.10 in-line.Revenue of $0.56M beats by $0.19M.Press Release
Seekingalpha · 11/12 21:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCX. Analyze the recent business situations of ONCOCYTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCX stock price target is 4.000 with a high estimate of 6.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 58
Institutional Holdings: 15.99M
% Owned: 23.78%
Shares Outstanding: 67.25M
TypeInstitutionsShares
Increased
14
1.97M
New
18
934.37K
Decreased
15
1.25M
Sold Out
13
1.79M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.07%
Pharmaceuticals & Medical Research
+0.39%
Key Executives
Chairman/Independent Director
Cavan Redmond
President/Chief Executive Officer/Director
Ronald Andrews
Chief Financial Officer
Mitchell Levine
Chief Operating Officer
Albert Parker
Senior Vice President/Chief Accounting Officer
Tony Kalajian
Senior Vice President/Director of Marketing
Padma Sundar
Chief Scientific Officer
Lyndal Hesterberg
Other
Douglas Ross
Independent Director
Andrew Arno
Independent Director
Melinda Griffith
Independent Director
Andrew Last
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About OCX
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment. Its initial focus will be confirmatory diagnostics, utilizing liquid biopsy technology, for use in conjunction with imaging to confirm initial diagnoses within certain oncology indications. In addition, it will be developing screening diagnostics as replacements for screening imaging procedures. For some indications, it will also be pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It offers diagnostic tests for lung, breast and bladder cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of OncoCyte Corp stock information, including AMEX:OCX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCX stock methods without spending real money on the virtual paper trading platform.